Reflections on Day 1 of the AACR20 Virtual Meeting Part 1 – through a series of postcards

For cancer conferences, 2020 will be the year of the Virtual Meeting. The easy going world as we knew it just a few months ago is suddenly no longer.

We already know that many countries will be maintaining social distancing until at least the end of the year and perhaps longer into 2021. In others, a mandatory 14-day quarantine already in place for people entering the country will likely deter travel. Who wants to travel to a conference – even presuming it is going ahead – only to have to stay at home for 14 days afterwards?

The net result is that virtual meetings are likely here to stay for the duration and in the next few months we’ll see how organizations such as AACR, ASGCT, ASCO, and EHA produce them.

As of yesterday, there were 47,000 registered attendees for part 1 of the AACR virtual meeting, which is largely focused on early clinical trials.

What were some of the take-homes from Day 1 at the AACR20 virtual meeting?

We listened to many of the sessions and in this post share what stood out for us.

If you missed it, do check out our AACR20 Previews and ongoing coverage plus we will be rolling out additional in-depth posts once the meeting is over.

To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the first annual AACR virtual meeting subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers